Nailing Down the Debate on Antibiotic Resistance in Post-Transplant Patients by Pattacini, Laura
February 16, 2015 SCIENCE SPOTLIGHT 
 
1 Volume 5, Issue 2 | Fred Hutchinson Cancer Research Center 
 
Nailing Down the Debate on Antibiotic Resistance 
in Post-Transplant Patients 
February 16, 2015 
     L Pattacini 
Following hematopoietic cell transplantion (HCT), the extreme neutropenia (decrease of neutrophil 
number) and the impairment of the immune response make the body more susceptible to bacterial 
infections. Gram-negative rod (GNR) bacteremias affect 5-10% of HCT patients and are associated 
with a higher mortality rate than gram-positive infections. To reduce the probability of such 
infections, the use of prophylactic antibiotics have been recommended by international guidelines. 
Among available antibiotic treatments, fluoroquinolones have been shown to reduce the rate of post-
transplant infections and mortality rates. Although these agents were thought to be less prone to 
resistance due to their unique molecular structure, excessive use in medicine and agriculture has led 
to increasing resistance throughout the world. 
Studies from investigators at the Fred Hutch Vaccine and Infectious Disease Division (VIDD) 
suggested an increase in gram-negative bacteremia events in allogeneic HCT recipients in recent 
years, raising the question of whether this increase was related to increased resistance to 
fluoroquinolones. In order to address this question, Epidemiology PhD student Arianna Miles-Jay 
from Dr. Steven Pergam's group in VIDD analyzed GNR bacteremia data from patients undergoing 
HCT at Seattle Cancer Care Alliance (SCCA). The group conducted a longitudinal retrospective 
study on data from patients that underwent HCT during an era in which levofloxacin (a member of 
the fluoroquinolone family) prophylaxis was standard practice for HCT recipients: January 2003 to 
December 2012. Results from the study were published in December in Biology of Blood and 
Marrow Transplantation. 
The study had two main purposes: first, to look at trends over time in the incidence of all GNR and 
FQ-resistant GNR bacteremia events in the first 100 days after HCT; and second, to compare the 
mortality rates following infection with FQ-sensitive versus resistant strains. "While antibiotics are a 
lifesaving necessity, especially in this high risk population, their widespread use does not come 
without consequences. Evaluating the local epidemiology of GNR infections, including antibiotic 
susceptibilities, is important for optimizing the standard of care for SCCA patients." said researcher 
Miles-Jay to introduce the reason for her interest. The study includes data from 2306 patients that 
underwent allogeneic HCT, of whom 12.1% experienced GNR bacteremia following transplantation.  
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The bacteremias increased in the period of time between 2003 and 2009, and then declined in the 
following years. Although the study was not set to explain why such patterns occurred, the authors 
speculated that several infection control interventions implemented at SCCA between 2009 and 
2010 played a role in the post-2009 decrease. The incidence rate of FQ-resistant GNR followed a 
similar trend as total GNR, implying that the increased rate of GNR bacteremias were not due major 
increases in resistant strains. However, survival analyses showed that patients with a FQ resistant 
GNR bacteriemia had a significantly higher post-event cumulative mortality than patients 
experiencing a FQ-sensitive event, a finding that persisted after adjusting the analyses for various 
parameters, such as underlying illness, age at transplantation and conditioning regimen. This higher 
rate could be possibly be explained by delays in appropriate antibiotic therapy or that the bacteria 
most likely to acquire a resistant phenotype were ones known to be associated with higher mortality.  
Even though this study was a retrospective analysis, the large sample size and the fact that it was 
conducted from the center's robust long term longitudinal data make this publication an important 
step in addressing evidence-based decisions on the use of fluoroquinolones prophylaxis at the 
center. 
Arianna Miles-Jay concludes: "Since there is no evidence of overall increasing rates of 
fluoroquinolone resistance among gram-negative bacteremia events, levofloxacin is still appears to 
be a viable option for neutropenic prophylaxis for HCT recipients at the SCCA. However, the 
mortality difference we observed between FQ-resistant and sensitive infections highlights the 
importance of continued vigilance when it comes to antibiotic resistant infections." 
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Image provided by Arianna Miles-Jay 
Incidence rate of first gram-negative bacteremia event by transplant 
year, 2003-2012. 
 
